Instrumentation Laboratory (IL) floats below price range assumed in prospectus
This article was originally published in Clinica
Instrumentation Laboratory (IL) has priced its initial public offering on Nasdaq at $12 a share, below the $16 assumed in the prospectus. Lead underwriter Salomon Brothers attributes the lower price to recent declines in the share price of similar companies and the tougher IPO market generally.
You may also be interested in...
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.